DiabeticRetinopathy Market, by Disease Type (Proliferative Diabetic Retinopathy andNon-proliferative Diabetic Retinopathy), by Treatment (Anti VascularEndothelial Growth Factor Therapy and Intraocular Steroid Injection), byDistribution Channel (Hospitals Pharmacies, Retail Pharmacies, and OnlinePharmacies), and by Geography (North America, Latin America, Europe, AsiaPacific, Middle East, and Africa) - Size, Share, Outlook, and OpportunityAnalysis, 2019 - 2027
Diabetic retinopathy is one ofthe complications of diabetes, in which blood vessels in the retina getsdamaged due to high blood glucose level. Retina is the light sensitive innerlining at the back of the eye. Diabetic retinopathy mostly affects both theeyes. As disease condition progresses, diabetic retinopathy symptoms includingfluctuating vision, blurred vision, impaired color vision or sometimes dark andempty areas in vision leads to vision loss. The line of treatment for diabeticretinopathy depending on the disease condition of the patient, may requirelaser surgery, intraocular injections, and anti (VEFG) vascular endothelialgrowth factor therapy.
Global Diabetic Retinopathy -Market Dynamics
Increasing incidence of diabetesalong with increasing cases of blindness due to diabetes are expected to drivethe diabetic retinopathy market growth. According to the International DiabeticFederation report, 2017, around 425 million adults of age group 20 to 79 yearsare suffering from diabetes. According to the International Agency for thePrevention of Blindness, 2016, one in three people having diabetes have high chancesof getting affected by diabetic retinopathy. Moreover, according to the articlepublished in The Lancet, 2018, the annual incidence of diabetic retinopathyranges from 2.2% to 12.7%, globally.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3313
Moreover, several launches andapprovals of new diabetic retinopathy medications are expected to boost growthof the diabetic retinopathy market over the forecast period. For instance, inMay 2019, Regeneron Pharmaceutical received the U.S. Food and DrugAdministration (FDA) approval for EYLEA, an aflibercept injection for diabetesretinopathy. EYLEA is the only vascular endothelial growth factor (VEGF)inhibitor approved in two dosing options for diabetes retinopathy, allowingdoctors to customize treatment as per patient need.
Global Diabetic RetinopathyMarket - Regional Insights
On the basis of geography, theglobal diabetes retinopathy market is segmented into North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa. North America accountedfor the largest market share in diabetes retinopathy market, owing to highprevalence of diabetic retinopathy in the region. According to the NationalHealth Interview Survey, 2016-17, around 8.6% people have diabetic retinopathyin the U.S.
Europe also exhibits high growthin diabetes retinopathy market due to high prevalence of diabetic retinopathy.According to a report presented by the University of Bonn, 2017, around 17.7%of diabetic patients have showed signs of moderate non-proliferative diabeticretinopathy while around 2% patients are affected by severe non-proliferativediabetic retinopathy in the Europe. Moreover, according to the same source,around 4.1% of adults aged 45 and above are reported to have vision loss due todiabetic retinopathy in the Europe.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/diabetic-retinopathy-market-3313
Asia Pacific region is also witnessinglucrative growth in diabetic retinopathy market due to increasing disposableincome, large patient pool, and innovation in diagnostic approach andgovernment health insurance policies. According to the journal of Diabetologyreport 2018, around 80 million people were suffering from diabetes in AsiaPacific region in 2017 and is expected to increase to 151 million by 2045.Furthermore, according to The Union Health Ministry’s first National Diabetesand Diabetic Retinopathy Survey conducted from 2015-2019, around 16.9% ofpeople are suffering from diabetic retinopathy in India.
Global Diabetic RetinopathyMarket - Competitive Landscape
Key players operating in theglobal diabetic retinopathy market include Novartis AG, RegeneronPharmaceuticals, Bayer Healthcare, Actavis Plc, Alimera Science, Pfizer Inc.,Hoffmann-La Roche Ltd, Abbott Laboratories Ltd, Sirnaomics, Glycadiapharmaceuticals, Boehringer Ingelheim, Therapeutics Inc, Ampio pharmaceuticals,Lupin ltd, and others.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3313
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
